The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

1 Francesca Forzano; 2 Olga Antonova; 3 Angus Clarke; 4 Guido de Wert; 5 Sabine Hentze; 6 Yalda Jamshidi; 7 Yves Moreau; 8 Markus Perola; 9 10 11 Inga Prokopenko; 12 Andrew Read; 13 Alexandre Reymond; 14 Vigdis Stefansdottir; 15 Carla van El; Maurizio Genuardi; 17 16; Genetics Executive Committee of the European Society of Human; Genetics Public and Professional Policy Committee of the European Society of Human

doi:10.1038/s41431-021-01000-x

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

1 Francesca Forzano, 2 Olga Antonova, 3 Angus Clarke, 4 Guido de Wert, 5 Sabine Hentze, 6 Yalda Jamshidi, 7 Yves Moreau, 8 Markus Perola, 9 10 11 Inga Prokopenko, 12 Andrew Read, 13 Alexandre Reymond, 14 Vigdis Stefansdottir, 15 Carla van El, Maurizio Genuardi, 17 16, Genetics Executive Committee of the European Society of Human, Genetics Public and Professional Policy Committee of the European Society of Human

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

Lingua originale	English
pagine (da-a)	493-495
Numero di pagine	3
Rivista	European Journal of Human Genetics
Volume	2022
DOI	https://doi.org/10.1038/s41431-021-01000-x
Stato di pubblicazione	Pubblicato - 2022

Keywords

genetic testing

Accesso al documento

10.1038/s41431-021-01000-x

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Francesca Forzano, ., Olga Antonova, ., Angus Clarke, ., Guido de Wert, ., Sabine Hentze, ., Yalda Jamshidi, ., Yves Moreau, ., Markus Perola, ., Inga Prokopenko, . . ., Andrew Read, ., Alexandre Reymond, ., Vigdis Stefansdottir, ., Carla van El, ., Genuardi, M., 16, ., Executive Committee of the European Society of Human, G., & Public and Professional Policy Committee of the European Society of Human, G. (2022). The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice. European Journal of Human Genetics, 2022, 493-495. https://doi.org/10.1038/s41431-021-01000-x

@article{3965c1e816a340ff91fb950c7f51842e,

title = "The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice",

abstract = "Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.",

keywords = "genetic testing, genetic testing",

author = "{Francesca Forzano}, 1 and {Olga Antonova}, 2 and {Angus Clarke}, 3 and {Guido de Wert}, 4 and {Sabine Hentze}, 5 and {Yalda Jamshidi}, 6 and {Yves Moreau}, 7 and {Markus Perola}, 8 and {Inga Prokopenko}, {9 10 11} and {Andrew Read}, 12 and {Alexandre Reymond}, 13 and {Vigdis Stefansdottir}, 14 and {Carla van El}, 15 and Maurizio Genuardi and 17 16 and {Executive Committee of the European Society of Human}, Genetics and {Public and Professional Policy Committee of the European Society of Human}, Genetics",

year = "2022",

doi = "10.1038/s41431-021-01000-x",

language = "English",

volume = "2022",

pages = "493--495",

journal = "European Journal of Human Genetics",

issn = "1476-5438",

publisher = "-NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW -S Karger AG:Allschwilerstrasse 10, CH-4009 Basel Switzerland:011 41 61 3061111, EMAIL: [email protected], INTERNET: http://www.karger.com, Fax: 011 41 61 3061234",

}

Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, Alexandre Reymond, Vigdis Stefansdottir, Carla van El, , Genuardi, M, 16, Executive Committee of the European Society of Human, G & Public and Professional Policy Committee of the European Society of Human, G 2022, 'The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice', European Journal of Human Genetics, vol. 2022, pagg. 493-495. https://doi.org/10.1038/s41431-021-01000-x

TY - JOUR

T1 - The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

AU - Francesca Forzano, 1

AU - Olga Antonova, 2

AU - Angus Clarke, 3

AU - Guido de Wert, 4

AU - Sabine Hentze, 5

AU - Yalda Jamshidi, 6

AU - Yves Moreau, 7

AU - Markus Perola, 8

AU - Inga Prokopenko, 9 10 11

AU - Andrew Read, 12

AU - Alexandre Reymond, 13

AU - Vigdis Stefansdottir, 14

AU - Carla van El, 15

AU - Genuardi, Maurizio

AU - 16, 17

AU - Executive Committee of the European Society of Human, Genetics

AU - Public and Professional Policy Committee of the European Society of Human, Genetics

PY - 2022

Y1 - 2022

N2 - Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

AB - Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

KW - genetic testing

UR - http://hdl.handle.net/10807/219715

U2 - 10.1038/s41431-021-01000-x

DO - 10.1038/s41431-021-01000-x

M3 - Article

SN - 1476-5438

VL - 2022

SP - 493

EP - 495

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

ER -

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo